Cargando…

Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata

Caralluma tuberculata, a medicinal and edible plant of the genus Caralluma, belongs to the family Asclepiadaceae. Traditionally, its succulent stems are used as folk medicine for life-threatening diabetes mellitus (DM) disease. Its antidiabetic potential is ascribed to the presence of various second...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Amir, Mashwani, Zia-ur-Rehman, Ahmad, Ilyas, Raja, Naveed Iqbal, Mohammad, Sher, Khan, Safir Ullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806359/
https://www.ncbi.nlm.nih.gov/pubmed/36601006
http://dx.doi.org/10.3389/fendo.2022.1029942
_version_ 1784862520971886592
author Ali, Amir
Mashwani, Zia-ur-Rehman
Ahmad, Ilyas
Raja, Naveed Iqbal
Mohammad, Sher
Khan, Safir Ullah
author_facet Ali, Amir
Mashwani, Zia-ur-Rehman
Ahmad, Ilyas
Raja, Naveed Iqbal
Mohammad, Sher
Khan, Safir Ullah
author_sort Ali, Amir
collection PubMed
description Caralluma tuberculata, a medicinal and edible plant of the genus Caralluma, belongs to the family Asclepiadaceae. Traditionally, its succulent stems are used as folk medicine for life-threatening diabetes mellitus (DM) disease. Its antidiabetic potential is ascribed to the presence of various secondary metabolites (e.g., pregnane glycosides, flavone glycosides, megastigmane glycosides, polyphenols, ferulic acid, quercetin, and bitter principles, among others) that act as effective and safe antidiabetic agents. The mechanisms of these bioactive secondary metabolites in C. tuberculata herbal medicine include lowering the blood glucose level, stimulating B cells of the pancreas to release more insulin, enhancing the sensitivity of the insulin receptor, inhibiting the action of glucagon and the hydrolysis of glycogen, and increasing the use of glucose in tissues and organ. However, overexploitation, alterations in natural environmental conditions, lower seed viability, and slow growth rate are responsible for the extinction of species from natural habitats, then becoming critically endangered species according to the International Union for Conservation of Nature Red List categories. Therefore, its limited availability does not meet the higher worldwide market demand of C. tuberculata as an antidiabetic drug. Thus, for its conservation and sustainable utilization, researchers across the globe are working on devising strategies to conserve and improve biomass along with the secondary metabolite profiles of C. tuberculata using in vitro approaches. The current review describes the recent progress on antidiabetic phytoconstituents, their cellular mechanisms, and their subsequent clinical outcomes in the drug discovery management of DM. Moreover, in vitro methods such as callus culture, micropropagation, and nano-elicitation strategies for conserving and producing bioactive secondary metabolites have been concisely reviewed and discussed.
format Online
Article
Text
id pubmed-9806359
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98063592023-01-03 Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata Ali, Amir Mashwani, Zia-ur-Rehman Ahmad, Ilyas Raja, Naveed Iqbal Mohammad, Sher Khan, Safir Ullah Front Endocrinol (Lausanne) Endocrinology Caralluma tuberculata, a medicinal and edible plant of the genus Caralluma, belongs to the family Asclepiadaceae. Traditionally, its succulent stems are used as folk medicine for life-threatening diabetes mellitus (DM) disease. Its antidiabetic potential is ascribed to the presence of various secondary metabolites (e.g., pregnane glycosides, flavone glycosides, megastigmane glycosides, polyphenols, ferulic acid, quercetin, and bitter principles, among others) that act as effective and safe antidiabetic agents. The mechanisms of these bioactive secondary metabolites in C. tuberculata herbal medicine include lowering the blood glucose level, stimulating B cells of the pancreas to release more insulin, enhancing the sensitivity of the insulin receptor, inhibiting the action of glucagon and the hydrolysis of glycogen, and increasing the use of glucose in tissues and organ. However, overexploitation, alterations in natural environmental conditions, lower seed viability, and slow growth rate are responsible for the extinction of species from natural habitats, then becoming critically endangered species according to the International Union for Conservation of Nature Red List categories. Therefore, its limited availability does not meet the higher worldwide market demand of C. tuberculata as an antidiabetic drug. Thus, for its conservation and sustainable utilization, researchers across the globe are working on devising strategies to conserve and improve biomass along with the secondary metabolite profiles of C. tuberculata using in vitro approaches. The current review describes the recent progress on antidiabetic phytoconstituents, their cellular mechanisms, and their subsequent clinical outcomes in the drug discovery management of DM. Moreover, in vitro methods such as callus culture, micropropagation, and nano-elicitation strategies for conserving and producing bioactive secondary metabolites have been concisely reviewed and discussed. Frontiers Media S.A. 2022-12-19 /pmc/articles/PMC9806359/ /pubmed/36601006 http://dx.doi.org/10.3389/fendo.2022.1029942 Text en Copyright © 2022 Ali, Mashwani, Ahmad, Raja, Mohammad and Khan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Ali, Amir
Mashwani, Zia-ur-Rehman
Ahmad, Ilyas
Raja, Naveed Iqbal
Mohammad, Sher
Khan, Safir Ullah
Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title_full Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title_fullStr Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title_full_unstemmed Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title_short Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata
title_sort plant in vitro cultures: a promising and emerging technology for the feasible production of antidiabetic metabolites in caralluma tuberculata
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806359/
https://www.ncbi.nlm.nih.gov/pubmed/36601006
http://dx.doi.org/10.3389/fendo.2022.1029942
work_keys_str_mv AT aliamir plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata
AT mashwaniziaurrehman plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata
AT ahmadilyas plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata
AT rajanaveediqbal plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata
AT mohammadsher plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata
AT khansafirullah plantinvitroculturesapromisingandemergingtechnologyforthefeasibleproductionofantidiabeticmetabolitesincarallumatuberculata